Q-omics provides the consensus-scored LMX1A profile across patient tissues and cancer cell-line models. LMX1A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, LMX1A is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, LMX1A RNA expression shows 9,835 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, COAD, and TGCT as cancer lineages where LMX1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMX1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMX1A survival associations across molecular data types. LMX1A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMX1A RNA expression–survival associations across cancer types. High LMX1A expression shows unfavorable associations in COAD, ACC and KIRP, but favorable associations in LGG, SCLC and PAAD. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for LMX1A RNA expression.
This table summarizes LMX1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LMX1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMX1A shows lower tumor expression in COAD, THCA, BLCA, HNSC, BRCA and READ. The COAD box plot shows higher LMX1A RNA expression in normal versus tumor tissue (log2 FC = −0.526, t-test p < 0.001).
This table shows molecular features associated with LMX1A in patient tissues and cancer cell lines. In patient samples, LMX1A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LMX1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
